• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by ViewRay Inc. (Amendment)

    6/22/23 6:04:56 AM ET
    $VRAY
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $VRAY alert in real time by email
    SC 13D/A 1 d518511dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE

    13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

    (Amendment No. 1 )*

     

     

    ViewRay, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    92672L107

    (CUSIP Number)

    Brad Nelson

    191 University Blvd, Suite 246

    Denver, Colorado 80206

    (239) 970-4085

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    June 16, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box  ☐

     

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      1    

      NAMES OF REPORTING PERSONS

     

      Farhad Fred Ebrahimi

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (See Instructions)

     

      PF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0 shares

         8  

      SHARED VOTING POWER

     

      17,482,838 shares

         9  

      SOLE DISPOSITIVE POWER

     

      0 shares

       10  

      SHARED DISPOSITIVE POWER

     

      17,482,838 shares

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      17,482,838 shares

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      9.53%

    14  

      TYPE OF REPORTING PERSON (See Instructions)

     

      IN

     

     

    - 2 -


      1    

      NAMES OF REPORTING PERSONS

     

      Mary Wilkie Ebrahimi

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (See Instructions)

     

      PF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0 shares

         8  

      SHARED VOTING POWER

     

      17,482,838 shares

         9  

      SOLE DISPOSITIVE POWER

     

      0 shares

       10  

      SHARED DISPOSITIVE POWER

     

      17,482,838 shares

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      17,482,838 shares

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      9.53%

    14  

      TYPE OF REPORTING PERSON (See Instructions)

     

      IN

     

     

    - 3 -


    Schedule 13D

    This Amendment No. 1 to Schedule 13D amends the Schedule 13D filed on April 27, 2023.

     

    ITEM 1.

    SECURITY AND ISSUER.

    This statement relates to the common stock, $0.01 par value per share, of ViewRay, Inc., a corporation organized under the laws of the State of Delaware, with its principal executive offices at 1099 18th Street, Suite 3000, Denver, CO 80202.

     

    ITEM 2.

    IDENTITY AND BACKGROUND.

    (a) This statement is being filed by Farhad Fred Ebrahimi and Mary Wilkie Ebrahimi (the “Reporting Persons”).

    (b) 191 University Blvd, Suite 246, Denver, Colorado 80206.

    (c) Farhad Fred Ebrahimi is a private investor, and Mary Wilkie Ebrahimi is not employed.

    (d) Neither of the Reporting Persons has, during the last five years, been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) Neither of the Reporting Persons has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding become (or remain) subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities law, or finding any violation with respect to such laws.

    (f) United States.

     

    ITEM 3.

    SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

    The Reporting Persons paid $4,589,811 from personal funds to acquire the Common Stock.

     

    ITEM 4.

    PURPOSE OF TRANSACTION.

    The Reporting Persons acquired shares of Common Stock in accordance with the Terms of certain PUT options that required the Reporting Persons to purchase the shares upon the occurrence of certain conditions that were not within the Reporting Persons’ control.

    The Reporting Persons have PUT options that could result in the acquisition of 2,487,300 additional shares.

    The Reporting Persons may make additional sales or purchases of Common Stock or other securities of the Issuer, either in the open market or in private transactions, depending on their evaluation of the Issuer’s business, prospects and financial condition, the market for the Common Stock or other securities, other opportunities available to them, general economic conditions, money and stock market conditions, and other future developments.

     

    - 4 -


    Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in:

    (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

    (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

    (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

    (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

    (e) Any material change in the present capitalization or dividend policy of the Issuer;

    (f) Any other material change in the Issuer’s business or corporate structure;

    (g) Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

    (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

    (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or

    (j) Any action similar to any of those enumerated above.

    The Reporting Persons reserve the right, subject to applicable law, to review or reconsider their position, change their purpose, take other actions (including actions that could involve one or more of the types of transactions or have one or more of the results described in (a) through (j) above, or formulate and implement plans or proposals with respect to any of the foregoing.

     

    ITEM 5.

    INTEREST IN SECURITIES OF THE ISSUER.

    (a) Farhad Fred Ebrahimi and Mary Wilkie Ebrahimi jointly hold 17,482,838 of the Issuer’s Common Stock. Based on the number of shares reported as outstanding in the Issuer’s 10-Q, filed with the Securities Exchange Commission on May 11, 2023, this represents 9.53% of the outstanding Common Stock of the Issuer.

     

    - 5 -


    (b) Number of shares as to which Farhad Fred Ebrahimi and Mary Wilkie Ebrahimi have:

    (i) sole power to vote or to direct the vote: 0 shares

    (ii) shared power to vote or to direct the vote: 17,482,838 shares

    (iii) sole power to dispose or to direct the disposition of: 0 shares

    (iv) shared power to vote or to direct the vote: 17,482,838 shares

    (c) The following transactions have been effected by the Reporting Persons in the last 60 days or since their last 13D:

     

    Date of
    Transaction

      

    Type of Transaction

       Quantity      Price per
    Share (in US
    Dollars) 1
     

    4/25/2023

       Purchase of Common Stock      1,800      $ 1.75  

    4/26/2023

       Purchase of Common Stock      7,100      $ 3.10  

    5/11/2023

       Purchase of Common Stock      37,100      $ 3.14 (A) 

    5/11/2023

       Purchase of Common Stock      5,200      $ 1.37 (B) 

    5/12/2023

       Purchase of Common Stock      100      $ 1.35  

    5/17/2023

       Purchase of Common Stock      175,000      $ 1.25  

    5/19/2023

       Purchase of Common Stock      2,600      $ 1.60  

    5/23/2023

       Purchase of Common Stock      490,500      $ 1.38 (C) 

    5/24/2023

       Purchase of Common Stock      334,700      $ 1.30  

    5/24/2023

       Purchase of Common Stock      27,700      $ 4.00  

    5/25/2023

       Purchase of Common Stock      212,400      $ 1.42 (D) 

    5/26/2023

       Purchase of Common Stock      40,000      $ 1.30  

    5/31/2023

       Purchase of Common Stock      86,400      $ 1.30  

    5/31/2023

       Purchase of Common Stock      308,600      $ 4.01 (E) 

    6/6/2023

       Purchase of Common Stock      154,200      $ 1.30  

    6/16/2023

       Purchase of Common Stock      82,400      $ 1.33 (F) 

    6/16/2023

       Purchase of Common Stock      269,300      $ 3.65 (G) 

     

    - 6 -


    Note 1: Price per share is reported except as noted below where multiple purchases were conducted on the same day within a one dollar price range, in which case the weighted average purchase price is reported. The Reporting Persons undertake to provide upon request by the staff full information regarding the number of shares purchased at each separate price.

     

      (A)

    – Price range $3.10 - $3.65

      (B)

    – Price range $1.25 - $1.75

      (C)

    – Price range $1.28 - $1.60

      (D)

    – Price range $1.25 - $1.60

      (E)

    – Price range $3.65 - $4.20

      (F)

    – Price range $1.30 - $1.75

      (G)

    – Price range $3.65 - $4.20

    All of these transactions were effected by the Reporting Persons through Fidelity Investments’ online brokerage.

    (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of the shares beneficially owned by any of the Reporting Persons.

    (e) Not applicable

     

    ITEM 6.

    CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

    The following PUT options are outstanding that may be exercised by the purchasers. The obligations to buy are subject to conditions which have not occurred and are beyond the Reporting Persons’ control.

     

    Expiration Date

      

    Type of Transaction

       Quantity      Strike Price  

    01/19/2024

       Obligation to buy      117,600      $ 3.50  

    01/19/2024

       Obligation to buy      120,300      $ 4.00  

    01/19/2024

       Obligation to buy      227,400      $ 4.00  

    01/19/2024

       Obligation to buy      290,500      $ 1.50  

    01/19/2024

       Obligation to buy      267,800      $ 4.00  

    01/19/2024

       Obligation to buy      299,900      $ 1.50  

    01/19/2024

       Obligation to buy      44,700      $ 2.00  

    01/19/2024

       Obligation to buy      187,300      $ 3.50  

    01/19/2024

       Obligation to buy      142,200      $ 4.00  

    01/19/2024

       Obligation to buy      2,000      $ 4.50  

    01/17/2025

       Obligation to buy      787,600      $ 1.50  

     

    - 7 -


    ITEM 7.

    MATERIAL TO BE FILED AS EXHIBITS.

    Exhibit A - Power of Attorney

    Exhibit B - Power of Attorney

    Exhibit C - Agreement regarding filing of joint Schedule 13D.

     

    - 8 -


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: June 22, 2023

     

    By:   /s/ Farhad Fred Ebrahimi*

    Name:

      Farhad Fred Ebrahimi
    By:   /s/ Mary Wilkie Ebrahimi**

    Name:

      Mary Wilkie Ebrahimi

     

    *By   /s/ Brad Nelson
      Brad Nelson as Attorney-in-Fact
    **By:   /s/ Brad Nelson
      Brad Nelson as Attorney-in-Fact

     

    *

    This Schedule 13D was executed by Brad Nelson pursuant to a Power of Attorney referenced in Exhibit A.

    **

    This Schedule 13D was executed by Brad Nelson pursuant to a Power of Attorney referenced in Exhibit B.

     

    - 9 -


    EXHIBIT INDEX

     

    Exhibit A -    Power of Attorney incorporated by reference to Exhibit A to the Schedule 13D filed on April 27, 2023.
    Exhibit B -    Power of Attorney incorporated by reference to Exhibit B to the Schedule 13D filed on April 27 2023.
    Exhibit C -    Agreement regarding filing of joint Schedule 13D incorporated by reference to Exhibit C to the Schedule 13D filed on April 27, 2023.

     

    - 10 -

    Get the next $VRAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRAY

    DatePrice TargetRatingAnalyst
    5/11/2023$4.00 → $1.00Buy → Neutral
    B. Riley Securities
    4/17/2023$7.00 → $1.25Buy → Hold
    Jefferies
    4/14/2023Outperform → Perform
    Oppenheimer
    4/14/2023Buy → Neutral
    BTIG Research
    4/14/2023$7.00 → $1.75Buy → Hold
    Stifel
    1/25/2022$7.00Buy
    Stifel
    1/11/2022$7.00Neutral → Buy
    B. Riley Securities
    10/14/2021$7.00Neutral
    B. Riley Securities
    More analyst ratings

    $VRAY
    SEC Filings

    See more
    • SEC Form 25-NSE filed by ViewRay Inc.

      25-NSE - ViewRay, Inc. (0001597313) (Subject)

      9/8/23 10:12:09 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ViewRay, Inc. (0001597313) (Filer)

      9/7/23 5:28:43 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form NT 10-Q filed by ViewRay Inc.

      NT 10-Q - ViewRay, Inc. (0001597313) (Filer)

      8/14/23 4:03:14 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Shah Sanket

      4 - ViewRay, Inc. (0001597313) (Issuer)

      7/26/23 5:05:01 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Podbelski Adam Andrew

      4 - ViewRay, Inc. (0001597313) (Issuer)

      7/26/23 5:04:48 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3: New insider Shah Sanket claimed ownership of 66,659 shares

      3 - ViewRay, Inc. (0001597313) (Issuer)

      7/26/23 5:03:11 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NUBURU Appoints Brian Knaley as new CEO

      NUBURU, Inc. ("NUBURU" or the "Company") (NYSE:BURU), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced the appointment of Brian Knaley as the Company's new Chief Executive Officer, replacing Dr. Mark Zediker, who has left the Company to pursue other opportunities. Mr. Knaley has also joined NUBURU's Board of Directors upon assuming the role. Mr. Knaley, who had served as the Company's Chief Financial Officer since February 2022, has over 25 years of experience in finance and operations. Prior to joining NUBURU, Mr. Knaley served as the chief financial officer of CEA Industries Inc. (NASDAQ:CEAD), a provider of controlled environmental

      11/1/23 4:30:00 PM ET
      $BURU
      $CEAD
      $VRAY
      Industrial Machinery/Components
      Miscellaneous
      Industrials
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets

      DENVER, July 21, 2023 /PRNewswire/ -- ViewRay, Inc. (the "Company") (NASDAQ:VRAY) announced today that on July 17, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code, and concerns about the Company's ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1), the Company's securities will be delisted from the Nasdaq Stock Market. The Company does not intend to appeal Nasdaq's determination. Trading of the Company's common st

      7/21/23 4:01:00 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay® Files Voluntary Chapter 11 Petitions

      Debtor-in-Possession Financing Secured to Support Ongoing Operations and Chapter 11 Process DENVER, July 17, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that it and certain of its subsidiaries (collectively, "the Company") filed voluntary petitions for relief (the "Petitions") under Chapter 11 of Title 11 the U.S. Bankruptcy Code ("Chapter 11") in the United States Bankruptcy Court for the District of Delaware (the "Court"). The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, including a sale of all or a portion of the Company's assets, while continuing to support its customers during the Chapter 11 pro

      7/17/23 7:00:00 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)

      SC 13G/A - ViewRay, Inc. (0001597313) (Subject)

      2/14/24 4:50:48 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)

      SC 13G/A - ViewRay, Inc. (0001597313) (Subject)

      2/12/24 6:26:25 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)

      SC 13G/A - ViewRay, Inc. (0001597313) (Subject)

      2/7/24 6:13:01 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ViewRay downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded ViewRay from Buy to Neutral and set a new price target of $1.00 from $4.00 previously

      5/11/23 6:49:02 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay downgraded by Jefferies with a new price target

      Jefferies downgraded ViewRay from Buy to Hold and set a new price target of $1.25 from $7.00 previously

      4/17/23 7:40:30 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay downgraded by Oppenheimer

      Oppenheimer downgraded ViewRay from Outperform to Perform

      4/14/23 8:06:57 AM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Leadership Updates

    Live Leadership Updates

    See more
    • NUBURU Appoints Brian Knaley as new CEO

      NUBURU, Inc. ("NUBURU" or the "Company") (NYSE:BURU), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced the appointment of Brian Knaley as the Company's new Chief Executive Officer, replacing Dr. Mark Zediker, who has left the Company to pursue other opportunities. Mr. Knaley has also joined NUBURU's Board of Directors upon assuming the role. Mr. Knaley, who had served as the Company's Chief Financial Officer since February 2022, has over 25 years of experience in finance and operations. Prior to joining NUBURU, Mr. Knaley served as the chief financial officer of CEA Industries Inc. (NASDAQ:CEAD), a provider of controlled environmental

      11/1/23 4:30:00 PM ET
      $BURU
      $CEAD
      $VRAY
      Industrial Machinery/Components
      Miscellaneous
      Industrials
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer

      DENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2022 Preliminary Results and Other Data (Unaudited)Received nine new orders for MRIdian systems totaling approximately $56 million, compared to seven new orders totaling approximately $41 million in the fourth quarter of 2021. A total of 32 orders were received for the twelve months ended December 31, 2022, compared to 28 orders for the twelve months ended December 31, 2021. Total backlog i

      1/9/23 6:00:00 AM ET
      $AXGN
      $MIRO
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • NUBURU Names Brian Knaley as Chief Financial Officer

      Three-time public company CFO joins NUBURU with deep experience in leading business transformation and optimization of financial processes on a global scale NUBURU®, the industry leader in high power and high brightness industrial blue lasers, today announced that it has appointed Brian Knaley as Chief Financial Officer. In this strategic role, Mr. Knaley will oversee all aspects of finance and investor relations as NUBURU accelerates and implements its growth strategy to expand the presence of its blue laser technology across target markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005131/en/Three-time public compan

      3/22/22 9:00:00 AM ET
      $CEAD
      $VRAY
      Industrial Machinery/Components
      Industrials
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VRAY
    Financials

    Live finance-specific insights

    See more
    • ViewRay Announces First Quarter 2023 Results

      DENVER, May 10, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Total revenue for the first quarter 2023 was approximately $22.5 million, primarily from three revenue units, compared to approximately $18.9 million, primarily from three revenue units, in the first quarter of 2022.Received 13 new orders for MRIdian systems, totaling $68.3 million.Total backlog increased to $411.0 million as of March 31, 2023, compared to approximately $331.0 million as of March 31, 2022.Cash and cash equivalents, inclusive of restricted cash, was $85.5 million as of March 31, 2023.Net l

      5/10/23 4:01:00 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023

      DENVER, May 9, 2023 /PRNewswire/ --ViewRay, Inc. (NASDAQ:VRAY) announced today details relating to the release of first quarter 2023 financial results. ViewRay will hold a conference call to discuss results on Wednesday, May 10, 2023 at 4:30 p.m. ET. The dial-in number is (833) 470-1428 for domestic callers. The confirmation number is 133683. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars." About ViewRay® ViewRay, Inc. (NASDAQ:VRA

      5/9/23 4:10:00 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023

      DENVER, April 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13, 2023, at 8:00 AM ET. The dial-in number for domestic callers is (888) 886-7786. The confirmation number is 56031524. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars". About ViewRay® ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MR

      4/12/23 5:25:00 PM ET
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care